Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    

ARIAD PHARMACEUTICALS, INC.
Mes dernières consult.
Most popular
  Report  
SummaryNewsCompany 
News SummaryMost relevantAll newsSector newsTweets

Ariad Pharmaceuticals, Inc. : ARIAD Announces Completion of Public Offering

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/29/2013 | 10:20pm CET

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the completion of its previously announced public offering of 15,307,000 shares of common stock at a public offering price of $19.60 per share. In addition, the underwriters have exercised an option to purchase an additional 1,182,893 shares at $19.60 per share to cover over-allotments. The total gross proceeds from the offering are approximately $323 million. Net proceeds to ARIAD are approximately $310 million after deducting underwriting discounts and commissions and estimated offering expenses.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company, Inc. acted as joint book-running managers and underwriters for the offering. BMO Capital Markets, Leerink Swann LLC, RBC Capital Markets, LLC and UBS Investment Bank acted as co-managers for the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A final prospectus supplement relating to the offering has been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 866-803-9204), the offices of Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 631-274-2806), or the offices of Jefferies & Company, Inc., Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About ARIAD

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. For more information about ARIAD, visit the company's website at www.ariad.com.

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
[email protected]
or
For Media
Liza Heapes, 617-621-2315
[email protected]


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARIAD PHARMACEUTICALS, INC
2017ARIAD PHARMACEUTICALS : Announces Submission of Marketing Authorization Applicat..
BU
2017ARIAD PHARMACEUTICALS : Enters into Definitive Agreement to Be Acquired by Taked..
PU
2017ARIAD PHARMACEUTICALS : Takeda to Acquire ARIAD Pharmaceuticals, Inc.
PU
2017ARIAD PHARMACEUTICALS : Acquisition May Not Be in the Best Interests of ARIA Sha..
PR
2017ARIAD SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces the Investigation of A..
PR
2017Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharm..
BU
2017ARIAD PHARMACEUTICALS, INC. : Ariad Pharmaceuticals Cash Acquisition by Takeda P..
AC
2017Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
RE
2017HARWOOD FEFFER LLP : Announces Investigation of ARIAD Pharmaceuticals, Inc.
PR
2017ARIAD PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation Of..
BU
More news
News from SeekingAlpha
20173 THINGS IN BIOTECH YOU SHOULD LEARN : April 30, 2017 
2017SNIPPET ROUNDUP : Aerie Stumbles On Safety; Stada Is Sold At Last 
2017First-Quarter Deal Making Shows Glimmers Of Growth 
2017WHAT TO WATCH IN Q2 : Upcoming Healthcare Regulatory Events 
2017Roche Looks Ready To Rule Another Cancer Niche 
Managers
NameTitle
Christophe M. Bianchi Co-President
Paris Panayiotopoulos Co-President & Director
Timothy P. Clackson CSO, President-Research & Development
Nicholas Ventresca Chief Information Officer & Senior Vice President
Sarah J. Schlesinger Director
Sector and Competitors
1st jan.Capitalization (M$)
ARIAD PHARMACEUTICALS, INC.0
GILEAD SCIENCES12.98%105 375
VERTEX PHARMACEUTICALS7.42%39 931
REGENERON PHARMACEUTICALS-14.08%34 113
BIOVERATIV INC92.71%11 243
GENMAB-0.97%10 344